This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Atreca, Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Amy Manning-Bog: Pioneering Innovations in Cancer Therapy
Introduction: Amy Manning-Bog, based in Fremont, California, is an innovative inventor in the field of biotechnology. With a focus on creating antibodies that target tumor tissue, her work is essential for both diagnosis and therapy in cancer treatment.
Latest Patents: Amy holds a patent for "Antibodies that bind tumor tissue for diagnosis and therapy." This patent features antibodies that bind to tumor tissue through a specific interaction with an extracellular RNA-protein complex. These antibodies not only play a critical role in inducing an immune response but also offer methods for inhibiting tumor cell growth. Furthermore, her patent details the methods of producing such antibodies, showcasing her contributions to advancing cancer treatment technology.
Career Highlights: Amy’s professional journey is marked by her role at Atreca, Inc., where she collaborates with a team dedicated to innovative research and development in cancer therapies. Her expertise and dedication have significantly impacted the biotechnology landscape, enhancing potential treatment options for patients.
Collaborations: Throughout her career, Amy has worked alongside notable colleagues, including Jeff DeFalco and Daniel Eric Emerling. These collaborations demonstrate her commitment to teamwork in advancing biotechnological solutions that could change the way we approach cancer diagnosis and therapy.
Conclusion: Amy Manning-Bog is a remarkable inventor whose contributions to cancer treatment through innovative antibody technology reflect her dedication and expertise. Her patent and collaborative efforts at Atreca, Inc. are vital in the ongoing fight against cancer, embodying the spirit of innovation that continues to drive advancements in medical science.